FBR Still Positive on Abeona Therapeutics (ABEO) Following DSMB Review of ABO-102
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- Nasdaq, S&P tumble as Netflix, chip stocks drag; AmEx boosts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Nasdaq tumbles, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Jabil falls after placing CEO on paid leave amid internal investigation
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
Abeona Therapeutics Announces Data Safety Monitoring Board Approves ABO-102 Dose Escalation for Second Cohort in Phase 1/2 Clinical Trial for Sanfilippo Syndrome Type A
October 5, 2016 7:03 AM EDTNEW YORK, NY and CLEVELAND, OH -- (Marketwired) -- 10/05/16 -- Abeona Therapeutics Inc. (NASDAQ: ABEO)
ABO-102 (AAV-SGSH) delivers first-in-man AAV-based gene therapy administered by single intravenous injection to treat CNS and peripheral manifestations of Sanfilippo syndrome type AData Safety Monitoring Board (DSMB) approves ABO-102 dose escalation for the high-dose cohortAbeona Therapeutics Inc. (NASDAQ: ABEO), a clinical-stage biopharmaceutical company focused on developing gene therapies for life-threatening rare... More
Abeona Therapeutics to Present at Jefferies Gene Editing & Gene Therapy Summit
October 4, 2016 7:03 AM EDTNEW YORK, NY and CLEVELAND, OH -- (Marketwired) -- 10/04/16 -- Abeona Therapeutics Inc. (NASDAQ: ABEO) a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, today announced that CEO & President, Timothy J. Miller, Ph.D., will be presenting for The Company at Jefferies Gene Editing & Gene Therapy Summit, October 11th at 11 am ET in New York City.
The following are the specific details regarding Abeona Therapeutics Presentation:
Event: Jefferies Gene Editing & Gene Therapy Summit
Date: Tuesday, October 11th, 2016
Time:... More
